

**PATIENT DETAILS**

Patient name:

DOB:

Phone:

Address:

Medicare:

Clinical trial / ID no.:

**EXAMINATION**

- PET with Whole Body Diagnostic CT (Head, Chest, Abdo, Pelvis)**  
 Plus Extremity (eg. Melanoma, Sarcoma, Myeloma, PUO, Vasculitis/Arteritis, Rheumatological or where limb involvement suspected)
- PET with localised diagnostic CT (please tick region/s)**  
 Head  Neck  Chest  Abdo  Pelvis  Extremity
- PET with Non-Diagnostic CT (attenuation correction)**

**CLINICAL NOTES**
**PSMA**

PSA:

Gleason score/ISUP grade group:

- Contrast Allergy  
 Renal Impairment  
 Surgery / Biopsy  
 Radiation Therapy  
 Chemotherapy  
 Prior Imaging (when and where)

**INDICATIONS**
**MBS ELIGIBLE ITEMS**

- Solitary Pulmonary Nodule (61523)  
 Non-Small Cell Lung cancer (61529)

**Breast**

- Staging (locally advanced) (61524)  
 Suspected metastatic or recurrent (61525)

**Brain Tumour**

- Residual or Recurrent Malignant Tumour (61538)

 **Refractory Epilepsy (61559)**
 **Melanoma (61553)**
 **Ovarian Carcinoma (61565)**
**Cervix Carcinoma**

- Primary Staging (61571)  
 Restaging (61575)

 **Colorectal Carcinoma (61541)**
 **Oesophageal/GOJ (staging) (61577)**
**Metastatic SCC Cervical Nodes**

- Unknown Primary (61610)

**Head & Neck**

- Staging (61598)  
 Restaging (61604)

**Hodgkins or NHL**

- Initial staging (61620)  
 First line therapy response (61622)  
 Restaging (61628)  
 Second line therapy response (61632)

**Sarcoma (excluding GIST)**

- Staging (61640)  
 Restaging/Residual/Recurrent (61646)

 **Diagnosis of Alzheimer's (61560)**
**PSMA**

- Prostate staging (61563)  
 Prostate recurrence (61564)

**MBS INELIGIBLE ITEMS**

- Other FDG PET**  
 **FES**  
 **FET**  
 **Amyloid**  
 **NaF**  
 **Y90 SIRT**  
 **Lu177 PSMA**  
 **Ra223 Xofigo**  
 **Other**

*MBS ineligible items will incur out of pocket fee. MBS items must be specialist referred.*

**REFERRING PRACTITIONER**

Name:

Provider number:

Follow up appointment:

Send copy to:

Signature:

Date:

**RADIOLOGIST**

Dr Andrew Ng

**PET SPECIALISTS**

 Dr Dalveer Singh  
 Dr Kevin Lee

<b>LUNG</b>		
<b>Solitary Pulmonary Nodule</b>	<b>61523</b>	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
<b>NSCLC</b>	<b>61529</b>	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
<b>BRAIN</b>		
<b>Brain</b>	<b>61538</b>	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
<b>Epilepsy</b>	<b>61559</b>	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
<b>Alzheimer's</b>	<b>61560</b>	FDG PET brain for diagnosis of Alzheimer's disease if clinical evaluation (by or in consultation with a specialist) is equivocal. Not repeatable within 12 months and not more than 3 per lifetime.
<b>GASTROINTESTINAL</b>		
<b>Colorectal</b>	<b>61541</b>	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
<b>Oesophageal/GOJ</b>	<b>61577</b>	Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.
<b>GYNAECOLOGY</b>		
<b>Ovarian</b>	<b>61565</b>	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
<b>Uterine Cervix</b>	<b>61571</b>	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
<b>Uterine Cervix</b>	<b>61575</b>	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
<b>HEAD &amp; NECK</b>		
<b>Head &amp; Neck</b>	<b>61598</b>	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer.
<b>Head &amp; Neck</b>	<b>61604</b>	Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy.
<b>MELANOMA</b>		
<b>Melanoma</b>	<b>61553</b>	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
<b>SCC</b>		
<b>Metastatic SCC unknown primary</b>	<b>61610</b>	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
<b>LYMPHOMA</b>		
<b>Lymphoma</b>	<b>61620</b>	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
<b>Lymphoma</b>	<b>61622</b>	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
<b>Lymphoma</b>	<b>61628</b>	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
<b>Lymphoma</b>	<b>61632</b>	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
<b>SARCOMA</b>		
<b>Bone or Soft Tissue Sarcoma</b>	<b>61640</b>	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
<b>Sarcoma</b>	<b>61646</b>	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
<b>BREAST</b>		
<b>PET Breast</b>	<b>61524</b>	Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.).
<b>PET Breast</b>	<b>61525</b>	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.).
<b>PSMA</b>		
<b>Prostate Staging</b>	<b>61563</b>	Whole Body PSMA PET for initial staging of intermediate to high risk prostate adenocarcinoma for previously untreated patient, considered for locoregional therapy with curative intent. Once per lifetime.
<b>Prostate Recurrence</b>	<b>61564</b>	Whole body PSMA PET for restaging of recurrent prostate adenocarcinoma of patient who has undergone prior locoregional therapy and considered suitable for further locoregional therapy to determine appropriate further therapy. Twice per lifetime.

## WINDSOR GARDENS

Level 1, 480 Specialist Centre, 480 North East Rd, Windsor Gardens SA 5087  
p: (08) 8164 5600 | f: (08) 8164 5045 | e: windsorgardens@qscan.com.au

**ELECTRONIC REFERRALS  
ARE ALSO AVAILABLE**



All images are digitally archived for ten years and can be accessed by your doctor online anytime.

Your doctor has recommended you attend Qscan Radiology Clinics. You may choose another provider but please discuss this with your doctor first.